美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Cadrenal Therapeutics, Inc.

1.08

+0.03002.86%

盤後：1.090.0076+0.70%16:13 EDT

成交量：5.48萬

成交額：5.81萬

市值：385.30萬

市盈率：-0.22

高：1.10

開：1.05

低：1.01

收：1.05

52周最高：14.64

52周最低：1.00

股本：356.76萬

流通股本：322.30萬

量比：0.48

換手率：1.70%

股息：- -

股息率：- -

每股收益(TTM):-4.8667

每股收益(LYR):-6.6394

淨資產收益率：-275.16%

總資產收益率：-125.93%

市淨率：0.94

市盈率(LYR):-0.16

資料載入中...

總覽公司新聞資訊公告

Cadrenal Therapeutics：FDA就CAD-1005三期研究優化主要終點定義達成一致

Cadrenal Therapeutics啓動三期臨床試驗，採用ISTH標準評估出血事件作為主要安全終點

Cadrenal Therapeutics：FDA同意CAD-1005三期試驗採用安慰劑對照聯合標準抗凝治療

Cadrenal Therapeutics宣佈：FDA Type D會議就CAD-1005治療肝素誘導性血小板減少症的III期註冊研究給出積極結果

Cadrenal Therapeutics公布2026年第二季度財報，並更新心臟急救護理業務與戰略合作進程

競爭對手三期臨床試驗終止，Cadrenal Therapeutics 鞏固CAD-1005在心臟急性重症監護領域的多適應症戰略

中期研究顯示，抗血栓藥物可降低風險，Cadrenal股價應聲上漲

Cadrenal Therapeutics宣佈根據納斯達克規則進行最高880萬美元的市價私募配售

Cadrenal Therapeutics宣佈CAD-1005二期研究入選2026年ISTH大會的突破性口頭報告

Cadrenal 治療公司擬就Tecarfarin用於川崎病向FDA申請罕見兒科疾病認定

Cadrenal Therapeutics推進CAD-1005多適應症戰略；啓動2a期急性腎損傷臨床計劃，旨在加速Bio 2026大會上的醫藥合作

Cadrenal Therapeutics任命Quang X. Pham為臨時首席財務官及臨時首席會計官

Cadrenal Therapeutics公布2026年第一季度財報並在完成FDA二期結束會議後更新CAD-1005三期研發進展

Cadrenal Therapeutics宣佈完成FDA二期臨床試驗結束會議確立CAD-1005治療肝素誘導血小板減少症的關鍵三期註冊路徑

Cadrenal Therapeutics公司公布二期數據：CAD-1005實現血栓事件絕對風險降低超25%

Cadrenal Therapeutics公司提交招股説明書股東擬轉售最高120萬股普通股

美國研究綜述-3M、CME 集團、Transdigm 集團

Cadrenal Therapeutics公布2025年第四季度財報披露CAD-1005項目二期臨床結束後獲FDA積極反饋

Cadrenal Therapeutics 強調研究支持12-LOX抑制在減少肥胖和2型糖尿病炎症中的作用

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/CVKD/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"CVKD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CVKD\",,,,,undefined,":{"symbol":"CVKD","market":"US","secType":"STK","nameCN":"Cadrenal Therapeutics, Inc.","latestPrice":1.08,"timestamp":1789588800000,"preClose":1.05,"halted":0,"volume":54819,"hourTrading":{"tag":"盘后","latestPrice":1.0876,"preClose":1.08,"latestTime":"16:13 EDT","volume":160,"amount":172.8076,"timestamp":1789589607191,"change":0.0076,"changeRate":0.007037,"amplitude":0.007037},"delay":0,"changeRate":0.028571428571428595,"floatShares":3223023,"shares":3567600,"eps":-4.866724,"marketStatus":"盤後交易","change":0.03,"latestTime":"09-16 16:52:49 EDT","open":1.05,"high":1.1,"low":1.01,"amount":58138,"amplitude":0.085714,"askPrice":1.19,"askSize":200,"bidPrice":1.02,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.866724,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"listingDate":1674190800000,"exchange":"NASDAQ","adjPreClose":1.05,"preHourTrading":{"tag":"盘前","latestPrice":1.04,"preClose":1.05,"latestTime":"09:29 EDT","volume":3281,"amount":3423.1194679,"timestamp":1789565399999,"change":-0.01,"changeRate":-0.009524,"amplitude":0.009524},"postHourTrading":{"tag":"盘后","latestPrice":1.0876,"preClose":1.08,"latestTime":"16:13 EDT","volume":160,"amount":172.8076,"timestamp":1789589607191,"change":0.0076,"changeRate":0.007037,"amplitude":0.007037},"volumeRatio":0.480471},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CVKD\",,,,,undefined,":{"symbol":"CVKD","floatShares":3223023,"roa":"-125.93%","roe":"-275.16%","lyrEps":-6.639405,"volumeRatio":0.480471,"shares":3567600,"dividePrice":0,"high":1.1,"amplitude":0.085714,"preClose":1.05,"low":1.01,"week52Low":1,"pbRate":"0.94","week52High":14.64,"institutionHeld":0,"latestPrice":1.08,"committee":-0.333333,"eps":-4.866724,"divideRate":0,"volume":54819,"delay":0,"ttmEps":-4.866724,"open":1.05,"prevYearClose":6.78,"prevWeekClose":1.09,"prevMonthClose":1.75,"prevQuarterClose":3.34,"fiveDayClose":1.19,"twentyDayClose":1.71,"sixtyDayClose":3.18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CVKD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"CVKD","fiscalQuarterEnding":"2026/06","expectedEps":-1.16,"name":null,"time":"盤後","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-1.14},{"market":"US","date":"2026-05-07","symbol":"CVKD","fiscalQuarterEnding":"2026/03","expectedEps":-1.51,"name":null,"time":"盤前","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-1.04},{"market":"US","date":"2026-03-31","symbol":"CVKD","fiscalQuarterEnding":"2025/12","expectedEps":-1.17,"name":null,"time":"盤前","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"pre","actualEps":-1.41},{"market":"US","date":"2025-11-10","symbol":"CVKD","fiscalQuarterEnding":"2025/09","expectedEps":-1.55,"name":null,"time":"盤前","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-1.31},{"market":"US","date":"2025-08-11","symbol":"CVKD","fiscalQuarterEnding":"2025/06","expectedEps":-1.6,"name":null,"time":"盤前","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"pre","actualEps":-1.87}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CVKD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CVKD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1775620800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CVKD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CVKD","date":"2026-09-15","current":-0.221915,"percent":1,"low":-6.5442,"twenty":-2.481224,"median":-1.441677,"eighty":-0.811675,"high":-0.327591,"avg":-1.748651,"sd":1.088944,"marketCap":3781647},"quantilePoints":[{"date":"2023-01-20","current":-6.5442,"twenty":-6.16384,"median":-5.593301,"eighty":-5.593301,"marketCap":47934449},{"date":"2023-01-27","current":-4.161603,"twenty":-5.973233,"median":-5.338088,"eighty":-4.549173,"marketCap":30482586},{"date":"2023-02-03","current":-3.812156,"twenty":-5.593301,"median":-4.511051,"eighty":-4.113951,"marketCap":27922980},{"date":"2023-02-10","current":-3.160912,"twenty":-5.38913,"median":-4.288675,"eighty":-3.488122,"marketCap":23152804},{"date":"2023-02-17","current":-3.573896,"twenty":-4.892266,"median":-4.082183,"eighty":-3.392818,"marketCap":26177793},{"date":"2023-02-24","current":-3.345166,"twenty":-4.587294,"median":-3.573896,"eighty":-3.380111,"marketCap":24502414},{"date":"2023-03-03","current":-2.875001,"twenty":-4.507652,"median":-3.569925,"eighty":-3.160912,"marketCap":21058580},{"date":"2023-03-10","current":-2.589089,"twenty":-4.478393,"median":-3.494476,"eighty":-3.058111,"marketCap":18964357},{"date":"2023-03-17","current":-2.271409,"twenty":-4.364918,"median":-3.399172,"eighty":-2.900415,"marketCap":16637442},{"date":"2023-03-24","current":-1.985498,"twenty":-4.145719,"median":-3.271465,"eighty":-2.525553,"marketCap":14543218},{"date":"2023-03-31","current":-2.239641,"twenty":-4.082183,"median":-3.15297,"eighty":-2.291105,"marketCap":16404750},{"date":"2023-04-06","current":-2.112569,"twenty":-4.082183,"median":-3.137086,"eighty":-2.249171,"marketCap":15473984},{"date":"2023-04-12","current":-2.229793,"twenty":-4.028178,"median":-3.11326,"eighty":-2.242818,"marketCap":16332616},{"date":"2023-04-21","current":-2.446133,"twenty":-3.866161,"median":-3.03114,"eighty":-2.237671,"marketCap":17917245},{"date":"2023-04-28","current":-2.366713,"twenty":-3.6692,"median":-2.946479,"eighty":-2.249171,"marketCap":17335516},{"date":"2023-05-05","current":-2.096686,"twenty":-3.573896,"median":-2.875001,"eighty":-2.188781,"marketCap":15357639},{"date":"2023-05-12","current":-1.444685,"twenty":-3.573896,"median":-2.612915,"eighty":-2.169752,"marketCap":17800899},{"date":"2023-05-19","current":-1.359704,"twenty":-3.569131,"median":-2.462017,"eighty":-2.077625,"marketCap":16753788},{"date":"2023-05-26","current":-1.284383,"twenty":-3.546035,"median":-2.446133,"eighty":-1.985498,"marketCap":15825717},{"date":"2023-06-02","current":-1.346224,"twenty":-3.517444,"median":-2.384186,"eighty":-1.928316,"marketCap":16587696},{"date":"2023-06-09","current":-1.503204,"twenty":-3.469062,"median":-2.334945,"eighty":-1.45944,"marketCap":18521951},{"date":"2023-06-16","current":-1.44612,"twenty":-3.43094,"median":-2.283322,"eighty":-1.45944,"marketCap":17818586},{"date":"2023-06-23","current":-1.484176,"twenty":-3.418233,"median":-2.263467,"eighty":-1.465148,"marketCap":18287496},{"date":"2023-06-30","current":-1.398551,"twenty":-3.367404,"median":-2.247583,"eighty":-1.465148,"marketCap":17232448},{"date":"2023-07-07","current":-1.417578,"twenty":-3.349614,"median":-2.226775,"eighty":-1.445833,"marketCap":17466903},{"date":"2023-07-14","current":-1.503299,"twenty":-3.286205,"median":-2.191989,"eighty":-1.443298,"marketCap":18523123},{"date":"2023-07-21","current":-1.637011,"twenty":-3.183023,"median":-2.150431,"eighty":-1.445833,"marketCap":20170670},{"date":"2023-07-28","current":-1.152922,"twenty":-3.160912,"median":-2.112569,"eighty":-1.436606,"marketCap":14205899},{"date":"2023-08-04","current":-1.14188,"twenty":-3.148205,"median":-2.045063,"eighty":-1.406161,"marketCap":14069843},{"date":"2023-08-11","current":-0.924489,"twenty":-3.132321,"median":-1.985498,"eighty":-1.379336,"marketCap":11854271},{"date":"2023-08-18","current":-0.791165,"twenty":-3.116437,"median":-1.961672,"eighty":-1.351057,"marketCap":10144725},{"date":"2023-08-25","current":-0.756633,"twenty":-3.058111,"median":-1.906237,"eighty":-1.33893,"marketCap":9701938},{"date":"2023-09-01","current":-0.782025,"twenty":-3.028503,"median":-1.714964,"eighty":-1.314525,"marketCap":10027520},{"date":"2023-09-08","current":-0.93325,"twenty":-2.992542,"median":-1.675857,"eighty":-1.277692,"marketCap":11966608},{"date":"2023-09-15","current":-0.791064,"twenty":-2.948067,"median":-1.596605,"eighty":-1.146297,"marketCap":10143423},{"date":"2023-09-22","current":-0.685541,"twenty":-2.919476,"median":-1.522232,"eighty":-1.104853,"marketCap":8790358},{"date":"2023-09-29","current":-0.680463,"twenty":-2.884531,"median":-1.503251,"eighty":-0.944749,"marketCap":8725245},{"date":"2023-10-06","current":-0.665229,"twenty":-2.792404,"median":-1.503204,"eighty":-0.904366,"marketCap":8529903},{"date":"2023-10-13","current":-0.649081,"twenty":-2.655802,"median":-1.479419,"eighty":-0.871399,"marketCap":8322842},{"date":"2023-10-20","current":-0.597183,"twenty":-2.61768,"median":-1.473616,"eighty":-0.791104,"marketCap":7657379},{"date":"2023-10-27","current":-0.503746,"twenty":-2.598619,"median":-1.465148,"eighty":-0.784463,"marketCap":6459285},{"date":"2023-11-03","current":-0.446871,"twenty":-2.525553,"median":-1.450877,"eighty":-0.769227,"marketCap":5730011},{"date":"2023-11-10","current":-0.446511,"twenty":-2.471547,"median":-1.444685,"eighty":-0.749525,"marketCap":5730011},{"date":"2023-11-17","current":-0.457674,"twenty":-2.462017,"median":-1.436606,"eighty":-0.722103,"marketCap":5873262},{"date":"2023-11-22","current":-0.507704,"twenty":-2.455663,"median":-1.417578,"eighty":-0.721088,"marketCap":6515283},{"date":"2023-12-01","current":-0.466807,"twenty":-2.446133,"median":-1.403307,"eighty":-0.699922,"marketCap":5990466},{"date":"2023-12-08","current":-0.471881,"twenty":-2.427072,"median":-1.388031,"eighty":-0.680463,"marketCap":6055580},{"date":"2023-12-15","current":-0.559052,"twenty":-2.387045,"median":-1.376708,"eighty":-0.648167,"marketCap":7174222},{"date":"2023-12-22","current":-0.56514,"twenty":-2.368619,"median":-1.351076,"eighty":-0.63015,"marketCap":7252358},{"date":"2023-12-29","current":-0.722638,"twenty":-2.366713,"median":-1.348603,"eighty":-0.629682,"marketCap":9273503},{"date":"2024-01-05","current":-0.635264,"twenty":-2.347652,"median":-1.341467,"eighty":-0.629743,"marketCap":8152244},{"date":"2024-01-12","current":-0.620651,"twenty":-2.315884,"median":-1.326907,"eighty":-0.629682,"marketCap":7964716},{"date":"2024-01-19","current":-0.953911,"twenty":-2.296823,"median":-1.312673,"eighty":-0.629723,"marketCap":12241388},{"date":"2024-01-26","current":-1.319238,"twenty":-2.284116,"median":-1.293897,"eighty":-0.63015,"marketCap":16929580},{"date":"2024-02-02","current":-1.430866,"twenty":-2.276174,"median":-1.320586,"eighty":-0.632524,"marketCap":18362083},{"date":"2024-02-09","current":-0.923467,"twenty":-2.265055,"median":-1.321934,"eighty":-0.637094,"marketCap":11850706},{"date":"2024-02-16","current":-0.791644,"twenty":-2.255525,"median":-1.298654,"eighty":-0.640854,"marketCap":10159050},{"date":"2024-02-23","current":-0.743847,"twenty":-2.252348,"median":-1.278807,"eighty":-0.643003,"marketCap":9545678},{"date":"2024-03-01","current":-0.714418,"twenty":-2.237671,"median":-1.221262,"eighty":-0.639426,"marketCap":9168018},{"date":"2024-03-08","current":-0.654241,"twenty":-2.228586,"median":-1.149822,"eighty":-0.640346,"marketCap":8395769},{"date":"2024-03-15","current":-1.139373,"twenty":-2.218452,"median":-1.14188,"eighty":-0.642618,"marketCap":9521837},{"date":"2024-03-22","current":-1.2068,"twenty":-2.196183,"median":-1.140626,"eighty":-0.643971,"marketCap":10085335},{"date":"2024-03-28","current":-1.225937,"twenty":-2.191989,"median":-1.148028,"eighty":-0.645513,"marketCap":10245260},{"date":"2024-04-05","current":-1.16485,"twenty":-2.176105,"median":-1.152922,"eighty":-0.647557,"marketCap":9734749},{"date":"2024-04-12","current":-0.835183,"twenty":-2.160222,"median":-1.146113,"eighty":-0.649081,"marketCap":6979692},{"date":"2024-04-19","current":-0.823306,"twenty":-2.140639,"median":-1.139373,"eighty":-0.654241,"marketCap":6880439},{"date":"2024-04-26","current":-0.81143,"twenty":-2.128453,"median":-1.124432,"eighty":-0.658604,"marketCap":6781187},{"date":"2024-05-03","current":-0.890734,"twenty":-2.112569,"median":-1.111003,"eighty":-0.664084,"marketCap":7443938},{"date":"2024-05-10","current":-0.929811,"twenty":-2.096686,"median":-1.0981,"eighty":-0.664287,"marketCap":7770510},{"date":"2024-05-17","current":-1.420575,"twenty":-2.049034,"median":-1.111003,"eighty":-0.665229,"marketCap":6885242},{"date":"2024-05-24","current":-1.383913,"twenty":-2.041092,"median":-1.124432,"eighty":-0.669767,"marketCap":6707548},{"date":"2024-05-31","current":-1.354187,"twenty":-2.034738,"median":-1.135559,"eighty":-0.672852,"marketCap":6563472},{"date":"2024-06-07","current":-1.651117,"twenty":-1.995028,"median":-1.145503,"eighty":-0.674597,"marketCap":8002633},{"date":"2024-06-14","current":-1.462522,"twenty":-1.985498,"median":-1.149334,"eighty":-0.676934,"marketCap":7088550},{"date":"2024-06-21","current":-1.516029,"twenty":-1.985498,"median":-1.156171,"eighty":-0.679183,"marketCap":7347887},{"date":"2024-06-28","current":-1.504138,"twenty":-1.985498,"median":-1.16485,"eighty":-0.680036,"marketCap":7290256},{"date":"2024-07-05","current":-1.592623,"twenty":-1.956907,"median":-1.185729,"eighty":-0.680463,"marketCap":7719123},{"date":"2024-07-12","current":-1.549057,"twenty":-1.928316,"median":-1.2068,"eighty":-0.68257,"marketCap":7507971},{"date":"2024-07-15","current":-1.520322,"twenty":-1.925139,"median":-1.2068,"eighty":-0.683272,"marketCap":7368698},{"date":"2024-08-02","current":-1.416942,"twenty":-1.921962,"median":-1.214031,"eighty":-0.683974,"marketCap":6867633},{"date":"2024-08-09","current":-1.111674,"twenty":-1.906237,"median":-1.225937,"eighty":-0.685541,"marketCap":6933267},{"date":"2024-08-16","current":-1.293659,"twenty":-1.846933,"median":-1.234183,"eighty":-0.690721,"marketCap":8068268},{"date":"2024-08-23","current":-1.172164,"twenty":-1.818901,"median":-1.225937,"eighty":-0.699354,"marketCap":7310532},{"date":"2024-08-30","current":-1.264569,"twenty":-1.714964,"median":-1.241521,"eighty":-0.700775,"marketCap":7886837},{"date":"2024-09-06","current":-1.377507,"twenty":-1.706882,"median":-1.245795,"eighty":-0.702272,"marketCap":8591209},{"date":"2024-09-13","current":-1.830972,"twenty":-1.706882,"median":-1.246644,"eighty":-0.711712,"marketCap":11419371},{"date":"2024-09-20","current":-1.918243,"twenty":-1.834164,"median":-1.261146,"eighty":-0.71433,"marketCap":11963659},{"date":"2024-09-27","current":-2.482935,"twenty":-1.908638,"median":-1.273231,"eighty":-0.715692,"marketCap":15485521},{"date":"2024-10-04","current":-1.950755,"twenty":-1.957258,"median":-1.289021,"eighty":-0.720072,"marketCap":12166433},{"date":"2024-10-11","current":-1.928578,"twenty":-1.985498,"median":-1.30307,"eighty":-0.721088,"marketCap":12028120},{"date":"2024-10-18","current":-2.789238,"twenty":-2.037954,"median":-1.318426,"eighty":-0.721575,"marketCap":17395865},{"date":"2024-10-25","current":-2.86453,"twenty":-2.049228,"median":-1.322439,"eighty":-0.722103,"marketCap":17865446},{"date":"2024-10-31","current":-3.933452,"twenty":-2.070731,"median":-1.331376,"eighty":-0.722465,"marketCap":24532076},{"date":"2024-11-08","current":-3.909452,"twenty":-2.133327,"median":-1.338437,"eighty":-0.727802,"marketCap":24382399},{"date":"2024-11-15","current":-3.259855,"twenty":-2.194086,"median":-1.341467,"eighty":-0.734352,"marketCap":24801495},{"date":"2024-11-22","current":-3.282348,"twenty":-2.233732,"median":-1.351028,"eighty":-0.73941,"marketCap":24972628},{"date":"2024-11-29","current":-3.558806,"twenty":-2.265055,"median":-1.353013,"eighty":-0.74173,"marketCap":27075962},{"date":"2024-12-06","current":-3.132405,"twenty":-2.307334,"median":-1.357489,"eighty":-0.742873,"marketCap":23831837},{"date":"2024-12-13","current":-2.717719,"twenty":-2.368619,"median":-1.360113,"eighty":-0.745058,"marketCap":20676837},{"date":"2024-12-20","current":-3.394806,"twenty":-2.438951,"median":-1.363105,"eighty":-0.747693,"marketCap":25828222},{"date":"2024-12-27","current":-3.854006,"twenty":-2.462017,"median":-1.369978,"eighty":-0.749448,"marketCap":29321894},{"date":"2025-01-03","current":-3.631435,"twenty":-2.481224,"median":-1.377507,"eighty":-0.751556,"marketCap":27628533},{"date":"2025-01-10","current":-3.877435,"twenty":-2.523165,"median":-1.379523,"eighty":-0.753182,"marketCap":29500143},{"date":"2025-01-17","current":-4.264007,"twenty":-2.624538,"median":-1.387215,"eighty":-0.756024,"marketCap":32441245},{"date":"2025-01-24","current":-4.636522,"twenty":-2.674136,"median":-1.387903,"eighty":-0.758704,"marketCap":35275397},{"date":"2025-01-31","current":-4.458465,"twenty":-2.840559,"median":-1.398551,"eighty":-0.76167,"marketCap":33920708},{"date":"2025-02-07","current":-4.474865,"twenty":-2.909946,"median":-1.409317,"eighty":-0.766663,"marketCap":34045482},{"date":"2025-02-14","current":-4.49595,"twenty":-2.953876,"median":-1.417578,"eighty":-0.770226,"marketCap":34205906},{"date":"2025-02-21","current":-4.50415,"twenty":-3.001398,"median":-1.420575,"eighty":-0.772831,"marketCap":34268293},{"date":"2025-02-28","current":-4.313207,"twenty":-3.066784,"median":-1.427287,"eighty":-0.777478,"marketCap":32815567},{"date":"2025-03-07","current":-3.912578,"twenty":-3.139979,"median":-1.436606,"eighty":-0.780079,"marketCap":29767516},{"date":"2025-03-14","current":-4.088293,"twenty":-3.197171,"median":-1.445403,"eighty":-0.780934,"marketCap":31104380},{"date":"2025-03-21","current":-3.441281,"twenty":-3.248668,"median":-1.453604,"eighty":-0.782025,"marketCap":36654345},{"date":"2025-03-28","current":-3.301865,"twenty":-3.277995,"median":-1.456931,"eighty":-0.78237,"marketCap":35169374},{"date":"2025-04-04","current":-2.968325,"twenty":-3.266821,"median":-1.464503,"eighty":-0.783762,"marketCap":31616722},{"date":"2025-04-11","current":-2.518311,"twenty":-3.259068,"median":-1.469382,"eighty":-0.787263,"marketCap":26823461},{"date":"2025-04-17","current":-2.85891,"twenty":-3.257859,"median":-1.474662,"eighty":-0.790653,"marketCap":30451302},{"date":"2025-04-25","current":-3.000091,"twenty":-3.257392,"median":-1.49369,"eighty":-0.791084,"marketCap":31955070},{"date":"2025-05-02","current":-2.911853,"twenty":-3.251752,"median":-1.503204,"eighty":-0.791261,"marketCap":31015215},{"date":"2025-05-09","current":-2.270277,"twenty":-3.230283,"median":-1.504138,"eighty":-0.792361,"marketCap":29135505},{"date":"2025-05-16","current":-2.217562,"twenty":-3.211785,"median":-1.51768,"eighty":-0.795364,"marketCap":28458997},{"date":"2025-05-23","current":-2.303286,"twenty":-3.207473,"median":-1.520322,"eighty":-0.798283,"marketCap":29559125},{"date":"2025-05-30","current":-2.048131,"twenty":-3.194675,"median":-1.522232,"eighty":-0.80779,"marketCap":26284611},{"date":"2025-06-06","current":-2.238922,"twenty":-3.17692,"median":-1.535185,"eighty":-0.81143,"marketCap":28733121},{"date":"2025-06-13","current":-2.297156,"twenty":-3.160912,"median":-1.541956,"eighty":-0.811839,"marketCap":29480458},{"date":"2025-06-20","current":-2.051962,"twenty":-3.160912,"median":-1.546017,"eighty":-0.812362,"marketCap":26333778},{"date":"2025-06-27","current":-1.575368,"twenty":-3.148205,"median":-1.553351,"eighty":-0.816087,"marketCap":20217419},{"date":"2025-07-03","current":-1.989132,"twenty":-3.137454,"median":-1.556427,"eighty":-0.819168,"marketCap":25527441},{"date":"2025-07-11","current":-1.992197,"twenty":-3.130448,"median":-1.575368,"eighty":-0.822233,"marketCap":25566775},{"date":"2025-07-18","current":-1.819029,"twenty":-3.122655,"median":-1.585907,"eighty":-0.824111,"marketCap":23344432},{"date":"2025-07-25","current":-1.748536,"twenty":-3.115288,"median":-1.592623,"eighty":-0.830969,"marketCap":22439761},{"date":"2025-08-01","current":-1.596822,"twenty":-3.112066,"median":-1.60755,"eighty":-0.83978,"marketCap":20492753},{"date":"2025-08-08","current":-1.687442,"twenty":-3.09327,"median":-1.615212,"eighty":-0.845488,"marketCap":21655715},{"date":"2025-08-15","current":-1.874525,"twenty":-3.081005,"median":-1.616467,"eighty":-0.850297,"marketCap":26445353},{"date":"2025-08-22","current":-1.806334,"twenty":-3.070504,"median":-1.637011,"eighty":-0.858896,"marketCap":25483332},{"date":"2025-08-29","current":-1.928207,"twenty":-3.05288,"median":-1.651282,"eighty":-0.863774,"marketCap":27202689},{"date":"2025-09-05","current":-1.815039,"twenty":-3.045161,"median":-1.654092,"eighty":-0.866712,"marketCap":25606143},{"date":"2025-09-12","current":-1.958675,"twenty":-3.041134,"median":-1.665783,"eighty":-0.875806,"marketCap":27632529},{"date":"2025-09-19","current":-1.935461,"twenty":-3.028991,"median":-1.685629,"eighty":-0.883586,"marketCap":27305032},{"date":"2025-09-26","current":-2.060236,"twenty":-3.01081,"median":-1.701972,"eighty":-0.884716,"marketCap":29065326},{"date":"2025-10-03","current":-2.058785,"twenty":-2.99162,"median":-1.71336,"eighty":-0.887838,"marketCap":29044858},{"date":"2025-10-10","current":-2.058785,"twenty":-2.977972,"median":-1.730146,"eighty":-0.89028,"marketCap":29044858},{"date":"2025-10-17","current":-2.005828,"twenty":-2.973266,"median":-1.744222,"eighty":-0.89604,"marketCap":28297756},{"date":"2025-10-24","current":-1.997849,"twenty":-2.966913,"median":-1.748536,"eighty":-0.904366,"marketCap":28185179},{"date":"2025-10-31","current":-1.874525,"twenty":-2.963428,"median":-1.767691,"eighty":-0.910735,"marketCap":26445353},{"date":"2025-11-07","current":-1.770062,"twenty":-2.961332,"median":-1.774587,"eighty":-0.921067,"marketCap":24971618},{"date":"2025-11-14","current":-1.657615,"twenty":-2.959148,"median":-1.761439,"eighty":-0.923876,"marketCap":23845849},{"date":"2025-11-21","current":-1.630588,"twenty":-2.955352,"median":-1.753133,"eighty":-0.926618,"marketCap":23457048},{"date":"2025-11-28","current":-1.354629,"twenty":-2.954378,"median":-1.747124,"eighty":-0.930499,"marketCap":19487202},{"date":"2025-12-05","current":-1.601728,"twenty":-2.954068,"median":-1.744222,"eighty":-0.934516,"marketCap":23041879},{"date":"2025-12-12","current":-1.587298,"twenty":-2.950868,"median":-1.73848,"eighty":-0.939656,"marketCap":22834295},{"date":"2025-12-19","current":-1.063489,"twenty":-2.940291,"median":-1.726315,"eighty":-0.940873,"marketCap":15298977},{"date":"2025-12-26","current":-1.063489,"twenty":-2.940291,"median":-1.71823,"eighty":-0.944523,"marketCap":15298977},{"date":"2026-01-02","current":-1.101967,"twenty":-2.938888,"median":-1.708991,"eighty":-0.944976,"marketCap":15852501},{"date":"2026-01-09","current":-1.280752,"twenty":-2.91719,"median":-1.701972,"eighty":-0.952147,"marketCap":18424440},{"date":"2026-01-16","current":-1.332762,"twenty":-2.904794,"median":-1.687875,"eighty":-0.957005,"marketCap":19172641},{"date":"2026-01-23","current":-1.241744,"twenty":-2.899853,"median":-1.679836,"eighty":-0.969272,"marketCap":17863290},{"date":"2026-01-30","current":-1.212489,"twenty":-2.893625,"median":-1.665783,"eighty":-0.98096,"marketCap":17442427},{"date":"2026-02-06","current":-0.867921,"twenty":-2.886524,"median":-1.656007,"eighty":-0.98096,"marketCap":12485598},{"date":"2026-02-13","current":-0.880923,"twenty":-2.881499,"median":-1.651447,"eighty":-0.944863,"marketCap":12672648},{"date":"2026-02-20","current":-1.009324,"twenty":-2.878053,"median":-1.641539,"eighty":-0.941701,"marketCap":14519768},{"date":"2026-02-27","current":-1.362018,"twenty":-2.873859,"median":-1.62773,"eighty":-0.944396,"marketCap":19593504},{"date":"2026-03-06","current":-1.299443,"twenty":-2.8691,"median":-1.617721,"eighty":-0.944749,"marketCap":18693325},{"date":"2026-03-13","current":-1.16698,"twenty":-2.862282,"median":-1.60245,"eighty":-0.948618,"marketCap":16787751},{"date":"2026-03-20","current":-1.132848,"twenty":-2.857498,"median":-1.596822,"eighty":-0.955458,"marketCap":16296745},{"date":"2026-03-27","current":-0.851668,"twenty":-2.854674,"median":-1.589961,"eighty":-0.944749,"marketCap":12251785},{"date":"2026-04-02","current":-0.865491,"twenty":-2.853417,"median":-1.587275,"eighty":-0.939656,"marketCap":11456822},{"date":"2026-04-10","current":-0.941191,"twenty":-2.848599,"median":-1.585719,"eighty":-0.93011,"marketCap":12458880},{"date":"2026-04-17","current":-0.918466,"twenty":-2.823863,"median":-1.582965,"eighty":-0.926432,"marketCap":12158062},{"date":"2026-04-24","current":-1.04724,"twenty":-2.784819,"median":-1.573829,"eighty":-0.927082,"marketCap":13862698},{"date":"2026-05-01","current":-1.551057,"twenty":-2.759024,"median":-1.555271,"eighty":-0.929709,"marketCap":20531907},{"date":"2026-05-08","current":-1.399905,"twenty":-2.724786,"median":-1.551057,"eighty":-0.93011,"marketCap":18531046},{"date":"2026-05-15","current":-1.36454,"twenty":-2.71069,"median":-1.547537,"eighty":-0.931696,"marketCap":16222361},{"date":"2026-05-22","current":-1.338647,"twenty":-2.679763,"median":-1.541956,"eighty":-0.934516,"marketCap":15914536},{"date":"2026-05-29","current":-1.29463,"twenty":-2.668509,"median":-1.537105,"eighty":-0.93958,"marketCap":15391235},{"date":"2026-06-05","current":-1.115971,"twenty":-2.647139,"median":-1.531678,"eighty":-0.939961,"marketCap":13267244},{"date":"2026-06-12","current":-1.043472,"twenty":-2.647139,"median":-1.522232,"eighty":-0.941191,"marketCap":12405335},{"date":"2026-06-18","current":-0.747912,"twenty":-2.638821,"median":-1.519662,"eighty":-0.938314,"marketCap":8891565},{"date":"2026-06-26","current":-0.690009,"twenty":-2.628688,"median":-1.514039,"eighty":-0.929033,"marketCap":8203186},{"date":"2026-07-02","current":-0.7648,"twenty":-2.625072,"median":-1.503718,"eighty":-0.92408,"marketCap":9092342},{"date":"2026-07-10","current":-0.726198,"twenty":-2.614313,"median":-1.503204,"eighty":-0.915436,"marketCap":8633423},{"date":"2026-07-17","current":-0.56214,"twenty":-2.59754,"median":-1.488933,"eighty":-0.902969,"marketCap":6683015},{"date":"2026-07-24","current":-0.489762,"twenty":-2.58972,"median":-1.474662,"eighty":-0.890464,"marketCap":5822541},{"date":"2026-07-31","current":-0.504237,"twenty":-2.586191,"median":-1.473616,"eighty":-0.884716,"marketCap":5994636},{"date":"2026-08-07","current":-0.45116,"twenty":-2.579965,"median":-1.46932,"eighty":-0.880724,"marketCap":5363621},{"date":"2026-08-14","current":-0.448747,"twenty":-2.553613,"median":-1.465148,"eighty":-0.866463,"marketCap":5334939},{"date":"2026-08-21","current":-0.491387,"twenty":-2.514854,"median":-1.460375,"eighty":-0.851932,"marketCap":5672471},{"date":"2026-08-28","current":-0.483661,"twenty":-2.498975,"median":-1.454925,"eighty":-0.838248,"marketCap":5583281},{"date":"2026-09-04","current":-0.395582,"twenty":-2.482251,"median":-1.447445,"eighty":-0.821697,"marketCap":4566517},{"date":"2026-09-11","current":-0.364677,"twenty":-2.481224,"median":-1.445403,"eighty":-0.813391,"marketCap":4209758},{"date":"2026-09-15","current":-0.327591,"twenty":-2.481224,"median":-1.441677,"eighty":-0.811675,"marketCap":3781647}],"updateTime":1789591969387},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CVKD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1158643487","title":"Cadrenal Therapeutics：FDA就CAD-1005三期研究優化主要終點定義達成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1158643487","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158643487?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 20:02","pubTimestamp":1788177763,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics（CVKD）宣布，美国食品药品监督管理局（FDA）已就CAD-1005三期临床研究优化后的主要终点定义达成一致意见。此次调整旨在更精准地评估药物疗效，为后续审评路径铺平道路。这一进展标志着该候选药物在关键性试验设计上迈出重要一步，有望加速其临床开发进程。公司表示，新定义将更好地反映治疗目标，同时兼顾统计学严谨性与临床实际意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157367322","title":"Cadrenal Therapeutics啓動三期臨床試驗，採用ISTH標準評估出血事件作為主要安全終點","url":"https://stock-news.laohu8.com/highlight/detail?id=1157367322","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157367322?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 20:02","pubTimestamp":1788177751,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics公司近日宣布，其即将开展的三期临床试验将采用国际血栓与止血学会（ISTH）制定的标准，把出血事件作为主要安全评价指标。这一决策标志着该公司在研药物研发进程中的重要里程碑。值得关注的是，该临床试验的设计紧扣临床实际需求，力求通过严谨的科学评估，全面衡量候选药物的安全性特征。通过将出血风险列为核心安全终点，研究团队期望能更精准地描绘出药物的风险-获益轮廓。此举不仅体现了监管层面对于出血风险的重视，也反映出企业在临床开发策略上日趋成熟与审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101522013","title":"Cadrenal Therapeutics：FDA同意CAD-1005三期試驗採用安慰劑對照聯合標準抗凝治療","url":"https://stock-news.laohu8.com/highlight/detail?id=1101522013","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101522013?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 20:01","pubTimestamp":1788177713,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics宣布，美国食品药品监督管理局（FDA）已同意其CAD-1005三期临床试验采用安慰剂对照联合标准抗凝治疗的方案。这一监管决定标志着该药物研发进程中的关键节点，为后续临床评估铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166554205","title":"Cadrenal Therapeutics宣佈：FDA Type D會議就CAD-1005治療肝素誘導性血小板減少症的III期註冊研究給出積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1166554205","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166554205?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 20:01","pubTimestamp":1788177675,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics对外宣布，其与FDA举行的Type D会议取得了积极成果。此次会议聚焦于CAD-1005在肝素诱导性血小板减少症治疗领域的III期注册研究方案。该公司对这一监管层面的积极信号表示欢迎，并认为这将有助于加速CAD-1005的临床开发进程。针对肝素诱导性血小板减少症这一严重且具有挑战性的适应症，该候选药物的潜在价值正逐步获得监管机构的认可。会议的积极结果，也预示着Cadrenal Therapeutics在满足未竟医疗需求方面，又向前迈出了坚实的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CVKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152151319","title":"Cadrenal Therapeutics公布2026年第二季度財報，並更新心臟急救護理業務與戰略合作進程","url":"https://stock-news.laohu8.com/highlight/detail?id=1152151319","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152151319?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 04:19","pubTimestamp":1786652373,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics于今日发布了2026年第二季度的财务业绩。与此同时，该公司还就其心脏急性危重症护理业务线，以及正在推进的战略合作伙伴遴选流程，提供了最新情况说明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CVKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150374108","title":"競爭對手三期臨床試驗終止，Cadrenal Therapeutics 鞏固CAD-1005在心臟急性重症監護領域的多適應症戰略","url":"https://stock-news.laohu8.com/highlight/detail?id=1150374108","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150374108?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 20:35","pubTimestamp":1785760540,"startTime":"0","endTime":"0","summary":"在竞争对手宣布终止其三期临床试验之后，Cadrenal Therapeutics 正着力强化其主打药物CAD-1005在心脏急性重症监护领域的多适应症布局。这一战略调整，彰显了该公司对市场动态的敏锐把握，以及其在心血管急症治疗赛道上的坚定决心。通过聚焦于更广泛的适应症组合，Cadrenal 旨在为临床医生提供更灵活、更具针对性的治疗选项，从而在竞争格局重塑之际，抢占先机。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CVKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651511410","title":"中期研究顯示，抗血栓藥物可降低風險，Cadrenal股價應聲上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2651511410","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651511410?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 21:11","pubTimestamp":1783948285,"startTime":"0","endTime":"0","summary":"BUZZ-中期研究显示，抗血栓药物可降低风险，Cadrenal股价应声上涨7月13日-** Cadrenal Therapeutics（CVKD.O）股价在盘前交易中上涨7.6%，至3.11美元** 该公司表示，在针对肝素诱导性血小板减少症（一种可能引发危险血栓的罕见免疫反应）的中期研究中，其实验性药物CAD-1005与安慰剂相比，将新发或恶化的血栓发生率降低了25%以上** CAD-1005 目","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nL4S43F14P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180034060","title":"Cadrenal Therapeutics宣佈根據納斯達克規則進行最高880萬美元的市價私募配售","url":"https://stock-news.laohu8.com/highlight/detail?id=1180034060","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180034060?lang=zh_tw&edition=fundamental","pubTime":"2026-07-01 08:02","pubTimestamp":1782864135,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics宣布，将依据纳斯达克市场规则，进行一项最高融资额达880万美元的私募配售，本次配售定价将采用市价基准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CVKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160715798","title":"Cadrenal Therapeutics宣佈CAD-1005二期研究入選2026年ISTH大會的突破性口頭報告","url":"https://stock-news.laohu8.com/highlight/detail?id=1160715798","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160715798?lang=zh_tw&edition=fundamental","pubTime":"2026-06-24 20:02","pubTimestamp":1782302553,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics宣布，其CAD-1005的二期临床研究已被选为2026年国际血栓与止血学会（ISTH）大会的突破性口头报告。这一入选标志着该研究在血栓与止血领域的重要进展获得了国际学术界的认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CVKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133455255","title":"Cadrenal 治療公司擬就Tecarfarin用於川崎病向FDA申請罕見兒科疾病認定","url":"https://stock-news.laohu8.com/highlight/detail?id=1133455255","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133455255?lang=zh_tw&edition=fundamental","pubTime":"2026-06-18 21:01","pubTimestamp":1781787690,"startTime":"0","endTime":"0","summary":"Cadrenal 治疗公司宣布，计划为其候选药物Tecarfarin在川崎病治疗中的应用，向美国食品药品监督管理局提交罕见儿科疾病认定申请。此举旨在加速该药物针对这一儿童血管炎症的研发与审批进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175510557","title":"Cadrenal Therapeutics推進CAD-1005多適應症戰略；啓動2a期急性腎損傷臨床計劃，旨在加速Bio 2026大會上的醫藥合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1175510557","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175510557?lang=zh_tw&edition=fundamental","pubTime":"2026-06-15 20:32","pubTimestamp":1781526775,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics正在积极推进其候选药物CAD-1005的多适应症开发战略。公司宣布启动一项针对心脏手术相关急性肾损伤（CSA-AKI）的2a期临床研究计划。此举旨在加速该药物的临床开发进程，并为即将到来的Bio 2026国际生物技术大会上的潜在医药合作伙伴关系奠定基础。通过展示CAD-1005在急性肾损伤这一未满足医疗需求领域的临床进展，公司期望能吸引合作伙伴，共同推进该药物在多个治疗领域的开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CVKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193713152","title":"Cadrenal Therapeutics任命Quang X. Pham為臨時首席財務官及臨時首席會計官","url":"https://stock-news.laohu8.com/highlight/detail?id=1193713152","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193713152?lang=zh_tw&edition=fundamental","pubTime":"2026-06-04 04:27","pubTimestamp":1780518468,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）提交的最新文件，Cadrenal Therapeutics, Inc. 已正式任命Quang X. Pham担任公司临时首席财务官及临时首席会计官。\n这一人事任命标志着该公司在关键财务领导职位上进行了重要调整。临时首席财务官将负责监督公司的整体财务战略、规划及报告工作，而临时首席会计官则将专注于会计操作、内部控制及财务合规性事务。\n公司此举旨在确保其财务职能在过渡期间的连续性与稳定性。新任命的两位临时职位预计将为Cadrenal Therapeutics的财务管理和会计实践带来专业的领导力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194469680","title":"Cadrenal Therapeutics公布2026年第一季度財報 並在完成FDA二期結束會議後更新CAD-1005三期研發進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1194469680","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194469680?lang=zh_tw&edition=fundamental","pubTime":"2026-05-07 20:30","pubTimestamp":1778157035,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics, Inc.披露了2026年第一季度的财务业绩，同时就核心药物CAD-1005的三期临床试验规划提供了最新动态。此次进展基于公司与美国食品药品监督管理局（FDA）成功举行的二期临床试验结束会议后所制定的后续开发路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CVKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149542500","title":"Cadrenal Therapeutics宣佈完成FDA二期臨床試驗結束會議 確立CAD-1005治療肝素誘導血小板減少症的關鍵三期註冊路徑","url":"https://stock-news.laohu8.com/highlight/detail?id=1149542500","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149542500?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 20:31","pubTimestamp":1777552310,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics近日宣布已顺利完成与美国食品药品监督管理局（FDA）针对CAD-1005药物治疗肝素诱导血小板减少症（HIT）的二期临床试验结束会议。此次会议明确了该药物进入关键性三期注册临床试验的路径规划，标志着CAD-1005在HIT治疗领域的研发进程迈入新阶段。\n此次会议成果为后续临床试验方案设计提供了明确指引。公司计划基于会议共识加快推进三期临床试验筹备工作，力争早日为HIT患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192319531","title":"Cadrenal Therapeutics公司公布二期數據：CAD-1005實現血栓事件絕對風險降低超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192319531","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192319531?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 20:31","pubTimestamp":1777552305,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics公司最新发布的二期临床试验数据显示，其核心候选药物CAD-1005在降低血栓事件发生率方面展现出突破性疗效。研究结果表明，与对照组相比，CAD-1005治疗组患者的血栓事件发生风险实现了超过25%的绝对降幅。\n这一显著疗效数据为CAD-1005的后续临床开发奠定了坚实基础。血栓性疾病作为全球范围内的主要健康威胁，新型治疗方案的突破备受医疗界关注。CAD-1005所展现的优异数据，不仅验证了其作用机制的有效性，更为患者带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CVKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120840144","title":"Cadrenal Therapeutics公司提交招股説明書 股東擬轉售最高120萬股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1120840144","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120840144?lang=zh_tw&edition=fundamental","pubTime":"2026-04-21 18:10","pubTimestamp":1776766215,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会最新披露文件显示，生物制药公司Cadrenal Therapeutics已正式提交招股说明书，公司现有股东计划通过二级市场转售最多120万股普通股。\n此次转售计划涉及由部分现有股东持有的公司普通股，总规模上限为120万股。招股说明书的提交标志着相关股东已获得通过公开市场减持股份的资格，为后续股份流通铺平道路。\n作为专注于心血管疾病创新疗法研发的临床阶段生物技术企业，Cadrenal Therapeutics此次股东股份转售安排引发市场关注。文件显示，此次股份转售将完全由售股股东自主进行，公司不会从此次售股中获得任何收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625162369","title":"美國研究綜述-3M、CME 集團、Transdigm 集團","url":"https://stock-news.laohu8.com/highlight/detail?id=2625162369","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625162369?lang=zh_tw&edition=fundamental","pubTime":"2026-04-08 16:14","pubTimestamp":1775636051,"startTime":"0","endTime":"0","summary":"美国研究综述-3M、CME 集团、Transdigm 集团路透4月8日 - 华尔街证券分析师周三修改了对几家美国上市公司的评级和目标价，其中包括 3M、CME 集团和 Transdigm 集团。要闻 * 3M公司MMM.N：加拿大皇家银行将目标价从136美元下调至125美元 * 芝商所 Inc CME.O：KBW恢复其市场表现评级；目标价305美元 * Transdigm Group Inc TDG.N：TD Cowen将目标价从1,565美元下调至1,450美元 以下是路透周三报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nL4S40R0OO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCHW","BK4533","LU0096364046.USD","ATI","DE","WMS","AX","CRS","IEX","ARES","HEI","GPN","BLK","CRL","IQV","LU0385154629.USD","FLS","BOEG","DOV","BAM","BMI","BOEU","CL","CVKD","APO","AME","CFG","CFR","CME","CARR","GE","CBOE","BOED","AMG","FTV","KKR","TDG","BX","ATKR","CATY","BA","FITB","FCNCA","DHR","LU1923622614.USD","MMM","LU0122379950.USD","CG","EMR","EWBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175758588","title":"Cadrenal Therapeutics公布2025年第四季度財報 披露CAD-1005項目二期臨床結束後獲FDA積極反饋","url":"https://stock-news.laohu8.com/highlight/detail?id=1175758588","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175758588?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 20:45","pubTimestamp":1774961149,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics公司近日发布了2025年第四季度财务报告，同时就CAD-1005研发项目的最新进展进行了说明。该项目在完成二期临床试验后，已与美国食品药品监督管理局（FDA）举行阶段性会议，并获得了积极反馈。\n此次财报披露了公司在第四季度的财务表现，而企业更新重点聚焦于CAD-1005项目的后续发展。该药物项目在达成二期临床终点后，与监管机构的沟通取得了关键进展，为后续研发路径奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107150282","title":"Cadrenal Therapeutics 強調研究支持12-LOX抑制在減少肥胖和2型糖尿病炎症中的作用","url":"https://stock-news.laohu8.com/highlight/detail?id=1107150282","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107150282?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 20:02","pubTimestamp":1773316933,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics 重点介绍了一项研究，该研究支持通过抑制12-脂氧合酶（12-LOX）来减轻肥胖及2型糖尿病相关的炎症反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}]}}